EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report

Cosimo Barbato iD, Vito A Lasorsa iD, Francesco Grimaldi, Santa Errichiello, Ida Pisano, Maurizio Capuozzo, Mariangela Capone, Viviana Izzo iD, Fabrizio Quarantelli iD, Alessandra Potenza iD, Roberta Visconti, Alessandra Galdiero und 8 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27020656 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Cosimo Barbato und 19 weiteren Autor:innen. Beteiligte Einrichtung: CEINGE Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy. Hauptthemen laut MEDLINE: Receptor, Platelet-Derived Growth Factor beta, Myeloproliferative Disorders, Protein Kinase Inhibitors, Gene Rearrangement. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases originating from hematopoietic stem cell transformation, characterized by the clonal proliferation of hematopoietic progenitors. A specific subset includes myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase (TK) gene fusions, particularly involving PDGFR A or B, which are sensitive to TK inhibitor treatment. We report a case of a 21-year-old patient with a myeloproliferative/myelodysplastic neoplasm, presenting with hyperleukocytosis, anemia, thrombocytopenia, and elevated LDH. The peripheral blood smear showed hypogranular neutrophils, eosinophils, basophils, and myeloid precursors. The absence of BCR::ABL1 and mutations in JAK2, CALR, and MPL excluded common MPNs. Cytogenetic analysis revealed a rearrangement between chromosomes 5 and 14. FISH analysis confirmed an inverted insertion from chromosome 5 to chromosome 14, involving the PDGFRB gene. WGS and RNAseq identified a fusion between PDGFRB and CCDC88C, causing the constitutive activation of PDGFRB. The fusion gene was confirmed by sequencing. This allowed for targeted therapy with a tyrosine kinase inhibitor (TKI), leading to molecular remission monitored by RT-qPCR. This case highlights how a multidisciplinary approach can identify atypical transcripts in MPN, guiding targeted therapy with TK inhibitors, thus resulting in effective treatment and molecular remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Platelet-Derived Growth Factor betaMyeloproliferative DisordersProtein Kinase InhibitorsGene RearrangementHumansYoung AdultMaleOncogene Proteins, FusionMolecular Targeted TherapyChromosomes, Human, Pair 5

Stichwörter der Autor:innen

CCDC88C genePDGFRB geneRNA sequencing (RNAseq)cytogeneticsimatinibmyeloproliferative neoplasms (MPNs)whole genome sequencing (WGS)

Substanzen

Receptor, Platelet-Derived Growth Factor betaPDGFRB protein, humanProtein Kinase InhibitorsOncogene Proteins, Fusion

Autor:innen und Institutionen

  • CEINGE Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy.
  • Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", 80131 Naples, Italy.
  • Hematology Section, Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80138 Naples, Italy.
  • UOSD Medical Genetics Laboratory, ASL Napoli 1 Centro, 80141 Naples, Italy.
  • UOC of Clinical Pharmacology, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', 84131 Salerno, Italy.
  • Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84084 Fisciano, Italy.

ORCID-Profile: Cosimo Barbato, Vito A Lasorsa, Viviana Izzo, Fabrizio Quarantelli, Alessandra Potenza, Novella Pugliese, Roberta Russo, Mario Capasso, Barbara Izzo

Zitieren

APA

Barbato, C., Lasorsa, V. A., Grimaldi, F., Errichiello, S., Pisano, I., Capuozzo, M., Capone, M., Izzo, V., Quarantelli, F., Potenza, A., Visconti, R., Galdiero, A., Zanniti, A., Prete, C. D., Femiano, T., Esposito, G., Pugliese, N., Russo, R., Capasso, M., & Izzo, B. (2026). Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020656

Vancouver

Barbato C, Lasorsa VA, Grimaldi F, Errichiello S, Pisano I, Capuozzo M, et al. Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020656

BibTeX
@article{Barbato2026,
  author = {Barbato, Cosimo and Lasorsa, Vito A and Grimaldi, Francesco and Errichiello, Santa and Pisano, Ida and Capuozzo, Maurizio and Capone, Mariangela and Izzo, Viviana and Quarantelli, Fabrizio and Potenza, Alessandra and Visconti, Roberta and Galdiero, Alessandra and Zanniti, Angelo and Prete, Ciro Del and Femiano, Teresa and Esposito, Giuseppina and Pugliese, Novella and Russo, Roberta and Capasso, Mario and Izzo, Barbara},
  title = {Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27020656}
}
Kostenlos starten →